Al­most all dos­es of Moun­jaro, Zep­bound in short sup­ply through Q2

The FDA up­dat­ed its drug short­ages list this week, not­ing that most of its in­jec­tions of di­a­betes drug Moun­jaro and weight loss drug Zep­bound will be in short sup­ply through the sec­ond quar­ter.

All but one dose of each drug — 2.5 mg of Moun­jaro and 2.5 mg of Zep­bound — are list­ed as ex­pe­ri­enc­ing “lim­it­ed avail­abil­i­ty,” ac­cord­ing to the FDA.

Zep­bound was ap­proved for weight loss in No­vem­ber and al­ready pulled in $175.8 mil­lion as of Feb­ru­ary. The com­pa­ny al­so an­nounced Wednes­day that it would file for a la­bel ex­pan­sion for the drug in sleep ap­nea this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER